Are Capmatinib and Savotinib similar?

Capmatinib (Capmatinib) and Savolitinib (Savolitinib) are drugs that belong to the tyrosine kinase inhibitor (TKI) class and are used to treat specific subgroups of patients with non-small cell lung cancer (NSCLC). The main target of capmatinib is MET kinase, especially in NSCLC patients with MET exon 14 skipping mutations. The main target of saivotinib is also MET kinase, and it is mainly used to treat NSCLC patients with MET exon 14 skipping mutations. Similar to capmatinib, saivotinib interferes with the growth and spread of cancer cells by inhibiting the activity of MET kinase. Which drug is better depends on the patient's specific situation, medical history, and doctor's recommendations.